In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scioderm Inc.

http://www.sderm.com

Latest From Scioderm Inc.

Breakthrough Designation Rescissions: Who Might US FDA Drop Next?

Our chart details the pipeline candidates who might lose the coveted status as treatment paradigms change and trial results come in.

Review Pathway Drug Review

Amicus Drops Epidermolysis Bullosa Candidate Following Phase III Failure

CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.

Clinical Trials Rare Diseases

Breakthrough Pace Shows No Signs Of Slowing

FDA started off 2016 with a spate of new breakthrough therapy designations, feeding the popular program – and fueling agency concerns about workforce strain.

BioPharmaceutical Regulation

Pipeline Progress: Highlights Of The J.P. Morgan Conference

Day-by-day updates from the J.P. Morgan Healthcare Conference Jan. 11-14 in San Francisco.

BioPharmaceutical Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register